Cargando…
OXavidin for Tissue Targeting Biotinylated Therapeutics
Avidin is a glycoprotein from hen egg white that binds biotin with very high affinity. Here we describe OXavidin, a product containing aldehyde groups, obtained by ligand-assisted sugar oxidation of avidin by sodium periodate. OXavidin chemically reacts with cellular and tissue proteins through Schi...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2814378/ https://www.ncbi.nlm.nih.gov/pubmed/20130784 http://dx.doi.org/10.1155/2009/921434 |
_version_ | 1782176992201801728 |
---|---|
author | De Santis, Rita Albertoni, Claudio Rosi, Antonio Leoni, Barbara Petronzelli, Fiorella D'Alessio, Valeria Nucera, Eleonora Salvatori, Giovanni Paganelli, Giovanni Verdoliva, Antonio Carminati, Paolo Nuzzolo, Carlo Antonio |
author_facet | De Santis, Rita Albertoni, Claudio Rosi, Antonio Leoni, Barbara Petronzelli, Fiorella D'Alessio, Valeria Nucera, Eleonora Salvatori, Giovanni Paganelli, Giovanni Verdoliva, Antonio Carminati, Paolo Nuzzolo, Carlo Antonio |
author_sort | De Santis, Rita |
collection | PubMed |
description | Avidin is a glycoprotein from hen egg white that binds biotin with very high affinity. Here we describe OXavidin, a product containing aldehyde groups, obtained by ligand-assisted sugar oxidation of avidin by sodium periodate. OXavidin chemically reacts with cellular and tissue proteins through Schiff's base formation thus residing in tissues for weeks while preserving the biotin binding capacity. The long tissue residence of OXavidin as well as that of OXavidin/biotinylated agent complex occurs in normal and neoplastic tissues and immunohistochemistry shows a strong and homogenous stromal localization. Once localized in tissue/tumor, OXavidin becomes an “artificial receptor” for intravenous injected biotin allowing tumor targeting with biotinylated therapeutics like radioisotopes or toxins. Moreover, present data also suggest that OXavidin might be useful for the homing of biotinylated cells. Overall, OXavidin exhibits a remarkable potential for many different therapeutic applications. |
format | Text |
id | pubmed-2814378 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2009 |
publisher | Hindawi Publishing Corporation |
record_format | MEDLINE/PubMed |
spelling | pubmed-28143782010-02-03 OXavidin for Tissue Targeting Biotinylated Therapeutics De Santis, Rita Albertoni, Claudio Rosi, Antonio Leoni, Barbara Petronzelli, Fiorella D'Alessio, Valeria Nucera, Eleonora Salvatori, Giovanni Paganelli, Giovanni Verdoliva, Antonio Carminati, Paolo Nuzzolo, Carlo Antonio J Biomed Biotechnol Research Article Avidin is a glycoprotein from hen egg white that binds biotin with very high affinity. Here we describe OXavidin, a product containing aldehyde groups, obtained by ligand-assisted sugar oxidation of avidin by sodium periodate. OXavidin chemically reacts with cellular and tissue proteins through Schiff's base formation thus residing in tissues for weeks while preserving the biotin binding capacity. The long tissue residence of OXavidin as well as that of OXavidin/biotinylated agent complex occurs in normal and neoplastic tissues and immunohistochemistry shows a strong and homogenous stromal localization. Once localized in tissue/tumor, OXavidin becomes an “artificial receptor” for intravenous injected biotin allowing tumor targeting with biotinylated therapeutics like radioisotopes or toxins. Moreover, present data also suggest that OXavidin might be useful for the homing of biotinylated cells. Overall, OXavidin exhibits a remarkable potential for many different therapeutic applications. Hindawi Publishing Corporation 2009 2010-01-10 /pmc/articles/PMC2814378/ /pubmed/20130784 http://dx.doi.org/10.1155/2009/921434 Text en Copyright © 2009 Rita De Santis et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article De Santis, Rita Albertoni, Claudio Rosi, Antonio Leoni, Barbara Petronzelli, Fiorella D'Alessio, Valeria Nucera, Eleonora Salvatori, Giovanni Paganelli, Giovanni Verdoliva, Antonio Carminati, Paolo Nuzzolo, Carlo Antonio OXavidin for Tissue Targeting Biotinylated Therapeutics |
title | OXavidin for Tissue Targeting Biotinylated Therapeutics |
title_full | OXavidin for Tissue Targeting Biotinylated Therapeutics |
title_fullStr | OXavidin for Tissue Targeting Biotinylated Therapeutics |
title_full_unstemmed | OXavidin for Tissue Targeting Biotinylated Therapeutics |
title_short | OXavidin for Tissue Targeting Biotinylated Therapeutics |
title_sort | oxavidin for tissue targeting biotinylated therapeutics |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2814378/ https://www.ncbi.nlm.nih.gov/pubmed/20130784 http://dx.doi.org/10.1155/2009/921434 |
work_keys_str_mv | AT desantisrita oxavidinfortissuetargetingbiotinylatedtherapeutics AT albertoniclaudio oxavidinfortissuetargetingbiotinylatedtherapeutics AT rosiantonio oxavidinfortissuetargetingbiotinylatedtherapeutics AT leonibarbara oxavidinfortissuetargetingbiotinylatedtherapeutics AT petronzellifiorella oxavidinfortissuetargetingbiotinylatedtherapeutics AT dalessiovaleria oxavidinfortissuetargetingbiotinylatedtherapeutics AT nuceraeleonora oxavidinfortissuetargetingbiotinylatedtherapeutics AT salvatorigiovanni oxavidinfortissuetargetingbiotinylatedtherapeutics AT paganelligiovanni oxavidinfortissuetargetingbiotinylatedtherapeutics AT verdolivaantonio oxavidinfortissuetargetingbiotinylatedtherapeutics AT carminatipaolo oxavidinfortissuetargetingbiotinylatedtherapeutics AT nuzzolocarloantonio oxavidinfortissuetargetingbiotinylatedtherapeutics |